Revenues (Tables)
|
9 Months Ended |
Sep. 30, 2021 |
|---|
| Revenues |
|
| Schedule of revenues disaggregated by category |
Revenues disaggregated by category were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
September 30, |
|
September 30, |
|
|
2021 |
|
2020 |
|
2021 |
|
2020 |
Product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Gross product sales |
|
$ |
20,546 |
|
$ |
20,318 |
|
$ |
58,692 |
|
$ |
54,042 |
Discounts and allowances |
|
|
(4,534) |
|
|
(4,029) |
|
|
(13,251) |
|
|
(10,099) |
Total product sales, net |
|
|
16,012 |
|
|
16,289 |
|
|
45,441 |
|
|
43,943 |
Revenues from collaborations: |
|
|
|
|
|
|
|
|
|
|
|
|
License revenues |
|
|
2,431 |
|
|
— |
|
|
70,354 |
|
|
39,858 |
Development milestones |
|
|
1,875 |
|
|
2,100 |
|
|
1,875 |
|
|
2,100 |
Research and development services and others |
|
|
225 |
|
|
— |
|
|
1,657 |
|
|
4,270 |
Total revenues from collaborations |
|
|
4,531 |
|
|
2,100 |
|
|
73,886 |
|
|
46,228 |
Government contract |
|
|
1,000 |
|
|
— |
|
|
9,500 |
|
|
— |
Total revenues |
|
$ |
21,543 |
|
$ |
18,389 |
|
$ |
128,827 |
|
$ |
90,171 |
|
| Schedule of revenues from product sales disaggregated by customers |
The following table summarizes the percentages of revenues from each of our customers who individually accounted for 10% or more (wherein * denotes less than 10%) of the total net product sales and revenues from collaborations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
September 30, |
|
September 30, |
|
|
2021 |
|
2020 |
|
2021 |
|
2020 |
ASD Healthcare and Oncology Supply |
|
|
25% |
|
|
48% |
|
|
15% |
|
|
26% |
McKesson Specialty Care Distribution Corporation |
|
|
35% |
|
|
34% |
|
|
17% |
|
|
20% |
Lilly |
|
|
12% |
|
|
— |
|
|
56% |
|
|
— |
Cardinal Healthcare |
|
|
18% |
|
|
* |
|
|
* |
|
|
* |
Grifols |
|
|
* |
|
|
* |
|
|
* |
|
|
49% |
Daiichi |
|
|
* |
|
|
11% |
|
|
* |
|
|
* |
|
| Schedule of product revenue allowance and reserve categories |
The following table summarizes activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2021 and 2020 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance at January 1, 2021 |
|
$ |
2,461 |
|
$ |
2,115 |
|
$ |
1,489 |
|
$ |
6,065 |
Provision related to current period sales |
|
|
7,326 |
|
|
3,995 |
|
|
739 |
|
|
12,060 |
Credit or payments made during the period |
|
|
(7,073) |
|
|
(3,367) |
|
|
(387) |
|
|
(10,827) |
Balance at September 30, 2021 |
|
$ |
2,714 |
|
$ |
2,743 |
|
$ |
1,841 |
|
$ |
7,298 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance at January 1, 2020 |
|
$ |
1,293 |
|
$ |
1,801 |
|
$ |
238 |
|
$ |
3,332 |
Provision related to current period sales |
|
|
5,625 |
|
|
2,775 |
|
|
676 |
|
|
9,076 |
Adjustment related to prior period sales |
|
|
(75) |
|
|
(490) |
|
|
565 |
|
|
— |
Credit or payments made during the period |
|
|
(5,020) |
|
|
(2,407) |
|
|
(72) |
|
|
(7,499) |
Balance at September 30, 2020 |
|
$ |
1,823 |
|
$ |
1,679 |
|
$ |
1,407 |
|
$ |
4,909 |
|